Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab, Retifanlimab, and Paclitaxel in Advanced Solid Tumors
NCT06320405Phase 2Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- May 2024
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of axatilimab in solid tumor, sponsored by OHSU Knight Cancer Institute. Started May 2024; status: recruiting.
02
Drugs
axatilimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06320405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06320405.